Helping patients reclaim a life of possibility
Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my options? What are the side effects? How will it affect my quality of life? The questions you have regarding your care choices are deeply personal…
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete the following application form. Deadline for submission is 3 pm CET on Friday 5th of November 2021
As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration…
Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects.